OOIR: Observatory of International Research

Papers

(The median citation count of Alzheimers & Dementia is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Dissecting the Neuropathological Contributors to Rapidly Progressive Dementia	1770
Effect of aging and neurodegeneration on contextual processing	1447
Differences in the brain transcriptome of glial genes due to aging and active DNA Aβ42 and passive MOAB anti‐Aβ immunotherapy in the 3xTg‐AD mouse strain	1419
	549
Binaural processing deficit and cognitive impairment in Alzheimer's disease	320
Neurochemical signs of astrocytic and neuronal injury in acute COVID‐19 normalizes during long‐term follow‐up	276
Higher ACE2 expression in the brains of individuals with Alzheimer’s disease	195
Transgender adults report greater cognitive and related functional challenges: Findings from the 2015‐2019 Behavioral Risk Factor Surveillance System	189
Tau pathology progression across PET‐based stages of regional amyloid deposition	184
Using deep learning models to examine the biological impact of polygenic risks for Alzheimer’s disease	182
Predicting Alzheimer’s disease progression in healthy and MCI subjects using multi‐modal deep learning approach	163
MIND and Mediterranean diet association with Alzheimer’s disease pathology	162
Smartphone ownership and usage in Chinese‐ and English‐speaking older adults	141
EEG biomarkers differentiate Lewy body dementia from Alzheimer’s disease	127
	126
Neuroinflammation in COVID‐19 and ADRD: Similarities, differences, and interactions	125
Tau deletion or loss of function promotes peripheral insulin resistance	123
Visual memory test equal to commonly used verbal memory test in predicting tau in the medial temporal lobe	121
The roles atherosclerotic cardiovascular disease risk and depression on cognitive outcomes in Mexican Americans and non‐Hispanic whites	120
Apathy across neurodegenerative disorders is associated with sex‐specific changes in sub‐cortical and cortical grey matter volumes	109
Associations among clinical characteristics of sleep quality, cognitive performance, and brain architecture in Thai dementia spectrum disorders	108
Is item response theory superior to classical test theory in scoring A‐IADL?	108
Objective subtle cognitive decline is associated with a more rapid increase in plasma phosphorylated‐tau181 levels over time	107
Differences in sex distribution between genetic and sporadic FTD	105
Reliability and participant acceptance of remotely administered RBANS in an MCI and Alzheimer’s disease cohort	105

Ten‐minute cognitive screening tool for mild cognitive impairment and prediction of pathological ß‐amyloid	104
Late‐onset epileptic seizures in adults with Down syndrome are linked to Alzheimer’s disease	100
Performance on autobiographical memory tests measuring contextual details is impaired in subjective cognitive decline and mild cognitive impairment	92
Dementia‐related agitation in Portuguese public hospitals: A retrospective analysis of 6,586 hospitalization episodes	91
Neurodegenerative diseases and lifetime seizure risk: A study of autopsy proven cases	89
Trajectories of self‐rated concerns in individuals developing cognitive decline	88
Neurocognitive effects of immune checkpoint inhibitors: A literature review	87
A stepwise approach towards diagnostic workup in dementia using online cognitive tools	87
Serious mini‐games for cognitive function assessment	85
Analysis of the ACE‐R’s sub‐items that best differentiate healthy controls, amnestic MCI and non‐amnestic MCI	85
Non‐fluent/agrammatic variant of primary progressive aphasia with progressive supranuclear palsy	76
Brain health actions: Evidence from the electronic Person‐Specific Outcome Measure (ePSOM) development programme	75
Self‐reported and informant‐reported depressive symptoms are independent and divergent predictors of new onset dementia in older adults	75
Adjustment to test, risk and diagnostic disclosures in people with mild cognitive impairment: An observational cohort study	74
Age‐dependent functional connectivity changes across large‐scale brain networks disrupt memory consolidation processes	72
Cognition may improve with medium‐chain triglyceride oil supplementation: A pilot study	71
At‐home assessment of cognitive performance: Establishing norm scores for the Cognitive Online Self‐Test Amsterdam (COST‐A)	69
Visual memory scores are associated with lateralization of tau in the medial temporal lobe	69
Social cognition provides early distinction between phenocopy syndrome of behavioural variant frontotemporal dementia and behavioural variant frontotemporal dementia	68
The effect of plasmalogen precursor supplementation on blood plasmalogen and C‐reactive protein levels and cognition in cognitively impaired persons	66
Examination of cognitive performance and mild behavioral impairment domains of apathy, mood, impulse dyscontrol, social inappropriateness and psychosis in cognitively normal adults aged 50 and over	65
Associations between obstructive sleep apnea, Alzheimer’s disease pathology, and objective daytime sleepiness measured by the psychomotor vigilance task in cognitively unimpaired adults	64
Does higher educational attainment influence functional capabilities among African Americans with Alzheimer’s disease?	64
MRI and CSF markers of mild behavioural impairment: Findings from the MEMENTO cohort study	63
Aetiology and prognosis of the motoric cognitive risk syndrome: A population‐based comparison with mild cognitive impairment	63
The heterogeneity of subjective cognitive decline: A data‐driven approach on a population‐based sample	57
Utility and usability of brief, remote, and self‐administered cognitive assessment for older adults with intact cognition and mild cognitive impairment: A novel approach to increase access during the	57
Precognize pilot study: A visuomotor ability‐based novel screening method for Alzheimer’s disease?	57
Lauric acid prevents the production of IL‐8 and IL‐13 and the increase of kynurenine/tryptophan ratio in LPS‐stimulated human astrocytes	54
High‐fat diet reduced dendritic spine density, but it did not affect cognitive function in spontaneous diabetic torii rats	54
Neurovascular unit dysfunction in Alzheimer’s disease	54
Associations of automatically segmented, enlarged perivascular spaces with neuropathology and cognition in community‐based older adults	53
Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau	52
Neuropathologic correlates of shape of subcortical brain structures	52
Progress towards brain organoid models with representative neurovascular features	51
Developments in understanding early onset Alzheimer's disease	50
Polygenic risk discriminates Lewy body dementia from Alzheimer's disease	50
The association between adult child education and cognitive functioning among older parents: A cross‐national comparison of diverse contexts	49
Paving the way for Alzheimer's disease blood‐based biomarkers in primary care	48
Lewy body co‐pathology in Alzheimer's disease and primary age‐related tauopathy contributes to differential neuropathological, cognitive, and brain atrophy patterns	48
Discovery and optimization of the first‐in‐class TDP‐43 PET tracer	47
Modulation of the Immunoproteasome Affects Pathological Tau Aggregation in Alzheimer’s Disease	47
LDs in AD: Lipid Droplet Dynamics are Modulated by APOE	46
Differential expression of mitochondrial energy producing genes in AD brains compromise ATP Synthesis and neuronal viability and stimulate inflammatory pathways and ROS synthesis	45
Spatial transcriptomics identifies disrupted circadian gene expression in a mouse model of Alzheimer’s disease	44
Deletion of microRNA‐21 exacerbates multiple phenotypes associated with Alzheimer’s disease through the RECK and ADAM10 pathway in a mouse model of Aβ amyloidosis	42
The role of the blood‐brain barrier in brain insulin signaling	41
Pseudo‐longitudinal trajectories of cerebrovascular disease biomarkers in adults with Down syndrome across the lifespan	41
Amyloid and tau fibrils induce different microglial phenotypes but converge to similar altered molecular processes	41
Administration of mitochondrial fusion promoter during ischemia and at the onset of reperfusion exert neuroprotective effects in rats with cardiac ischemia/reperfusion injury	41

Long term high‐fat feeding induces cognitive impairment, alterations in microglial morphology, and spatial transcriptomic changes	41
Mechanistic insights into the therapeutic potential of Angiotensin type 2 receptors (AT2R) in shaping behavior of astrocytes and microglia during hypertensive state	41
Activation of Wnt/β‐catenin pathway in the brain endothelium mitigates Aβ‐induced blood‐brain barrier dysfunction in Alzheimer’s disease	41
Characteristics of AD‐brain tau aggregate internalisation by human astrocytes and the responses induced	40
Neuroprotective potential of safinamide mesylate in streptozotocin induced sporadic Alzheimer’s disease in rats	40
Mitochondrial Localized Amyloid Precursor Protein Alters Mitochondrial Function and Mitophagy	40
Longitudinal white matter hyperintensities in Down’s syndrome	39
Protective effects of gestational folic acid and egg yolk powder solution intubation on motor coordination, anxiety, cognition, acetylcholinesterase activity and DNA fragmentation in prenatal alcohol	39
Understanding the role of the mitochondrial AD risk gene LACTB in myeloid cells.	39
GM1 modulates amyloid‐beta activation of NLRP3 inflammasome in microglia through Akt/mTOR‐mediated regulation of autophagy	38
Role of Onset of Diabetes on Development of Cognitive Impairment in Rats	38
Alzheimer’s disease induces pathological changes in the lungs of humans and the App^NL‐G‐F mouse model	37
FERMT2 cleavage impacts APP metabolism in a Src‐dependent manner	37
All‐in‐Human Target Discovery in Alzheimer’s Disease and Resilient Brains	37
Progressive dysregulation of circular RNAs in the hippocampus of a transgenic mouse model of amyloidosis	37
Myeloid Differentiation Factor 2 Inhibition Protects Against Doxorubicin‐induced Microglial Activation and Senescence	37
Elucidating Cell Diversity and Functions of Human Brain Borders in Alzheimer’s Disease	36
Differential Effects of Anticholinergic Medications in a Human Neuronal Model of AD	36
Influence of physiological glucose levels on SIM‐A9 microglial cell immune response	35
Chronic kidney disease is associated with cognitive dysfunction and cardiovascular remodeling in aged male and female Sprague‐Dawley rats	35
Longitudinal Quantification of Sub‐Regional Hippocampal Amyloid‐Beta Burden in Ex‐Vivo slices from the App^NL‐G‐F Mouse Model of Alzheimer’s Disease	35
ApoE4 is associated with higher lipid peroxidation but not protein nitration in AD brains	35
Lack of TREM2 and TYROBP effects on microglial homeostasis, activation and disease	35
Syzigium aromaticum may protect against paraquat mediated toxicity via p53 and Sestrin2 modulation	35
Early loss of microglial p38α MAPK in the APPswe/PS1dE9 mouse model of Alzheimer’s disease alters soluble amyloid beta and reduces microglia co‐localization with amyloid plaques without affecting amyl	35
Association between plasma inflammatory biomarkers and [¹⁸F]FDG‐PET signal in a transgenic amyloid rat model	35
iPSC‐derived cortical neurons of sporadic Alzheimer’s disease patients reflect their clinical vulnerability	34
SORL1 regulates tau trafficking	34
NETS‐seq advances the understanding of neuronal vulnerability in AD progression facilitating the identification of novel therapeutic targets at the single cell type level	33
A novel role for APP in neural circuit function	33
Ex vivo identification of transcriptional regulation landscape and potential therapeutic targets against ER stress using Alzheimer’s disease patient‐derived dermal fibroblast: findings from BICWALZS c	33
Statin therapy reduces the risk of AD: Clinic to bench translation for protective mechanism	33
Use of Inflammatory Panels to Distinguish Alzheimer’s Disease in a Down Syndrome Population	33
Roles of HDAC6 in the pathogenesis of Alzheimer’s disease	33
Transient CSF1R Inhibition in the Early Stage of AD Retains Homeostatic Microglia with Reduced Inflammasomes and Increased autophagy in the 5XFAD Model	32
Neuronal SIRPα modulates disease pathology and progression in a mouse model of Alzheimer’s disease	32
Clinical criteria for limbic‐predominant age‐related TDP‐43 encephalopathy	32
PSEN2 poison exon inclusion is common across brain regions in late‐onset Alzheimer’s disease	32
Role of primary cerebrovascular cilia in the pathogenesis of blood pressure and Alzheimer’s disease manifestations	32
Fibrillar tau induces blood brain barrier permeability, endothelial cell activation and bioenergetic alterations	32
Applying recommendations for diagnostic disclosure of mild cognitive impairment and dementia: Practical guidance for clinicians	32
Understanding the molecular mechanisms of TDP‐43 neurotoxicity in ALS and FTD to inspire targeted therapies	32
Herpes Simplex Virus‐1 Proteins Drive Alzheimer’s Disease Pathologies in Humans	32
Multiomics of iPSC‐derived ApoE3‐ and ApoE4 astrocytes and microglia uncovers cell type specific dysregulation of immunometabolism	32
Glutamate Release and Uptake in CNS of Young and Aged Mice Compared to a Knock‐In Mouse Model of Alzheimer’s Disease	32
Comparative Toxicogenomics Database: A tool to investigate the effects of environmental exposures on the etiology of Alzheimer’s disease	31
APOEe4*TREM2 and sickle cell trait in a late onset Alzheimer’s disease mouse model	31
Issue Information	31
Neuroprotective Potential of Limonene in LPS induced Parkinson’s Disease in Rats	31
Hsp40 molecular chaperones are potent regulators of tau seeding and accumulation	31
Regulation of meningeal lymphatic function by APOE	31
NEUROPROTECTIVE EFFECT OF PERILLYL ALCOHOL IN EXPERIMENTAL SPORADIC AD	31
Functional investigation of the gliovascular niche‐related genes and their relevance to Alzheimer’s disease pathomechanisms in zebrafish	30
TNFα‐mediated inflammation in mouse models of VCID	30
Ameliorative effects of Aqueous Fruit Pulp Extracts of Adansonia digitata on the Hippocampus of Aluminium Chloride‐treated Adult Wistar Rats	30
A comparative study of medication profiles from AD, MCI, and non‐demented patients	30
Ascorbate insufficiency disrupts neuronal transmission by surface electroencephalogram in a mouse model of Alzheimer’s disease	30
Overview on epidemiology and neuropathologic staging of limbic‐predominant age‐related TDP‐43 encephalopathy neuropathologic changes (LATE‐NC)	30
B cell and T cell populations are altered in the brain‐draining lymph nodes of the senescence accelerated mouse prone 8 (SAMP8)	30
Role of Peroxiredoxin 6 in the Development of Tau Pathology	29
Understanding the protective effect of the PLCG2 P522R variant in human microglia	29
Lifestyle Modification Exerts Protection Against Obesity‐Induced Neurodegeneration Via CD147‐Related Mechanism	29
Nanobodies: a promising tool to perturb ApoE4 activity in Alzheimer’s disease pathology	29
Serine‐129 phosphorylation of α‐synuclein is a trigger for physiologic protein‐protein interactions and synaptic function	29
The role of Alzheimer’s risk factor ApoE4 on intracellular Aβ aggregation	29
A3 receptor as a target for the treatment of Alzheimer’s disease	29
Vagus Nerve Stimulation Provides Neuroprotection Against Doxorubicin‐induced Chemobrain Via Activations of Both Muscarinic and Nicotinic Acetylcholine Receptors	29
Adaptive immune response in Alzheimer’s disease: untangling the role of ApoE4	28
Amyloid beta and tau pathology compared within different Alzheimer’s disease mouse models after inoculation with Alzheimer’s disease brain tissue	28
Reduced density of serotonergic axons without prominent neuron loss or tau pathology in the dorsal raphe nucleus in App knock‐in mouse models of amyloid‐β pathology	28
Olfactory Mucosal Cells of Individuals with Alzheimer’s Disease Display Alterations Similar to the Alzheimer Brain	28
Investigating two pore potassium channel THIK‐1 expression in Alzheimer’s disease	28
Depletion of microglia with CSF1R inhibitor prevents tau aggregation in the mouse model Thy1P301S	28
Investigating the role of ketogenic conditions on cholesterol metabolism and neuroinflammation in APOE4 carriers	27
Pharmacologically targeted mitochondrial fission/fusion performs neuroprotection against trastuzumab‐induced cognitive deficits in rats via suppressing mitochondrial dysfunction and oxidative stress	27
Leveraging the full potential of Raman spectroscopy for the identification of amyloid aggregation states	27
Lipopolysaccharide aggravates depressive‐like behavior via increasing microglial inflammation, decreasing microglial ramification, and altering tryptophan level in obese rats	27
The role of Kir6.2‐KATP channels in modulating sleep, brain metabolism, and neuronal excitability in AD	27
Identification of a Novel Mechanism Fostering the Alterations of Brain Energy Metabolism: a Link Between AD and T2DM	27
Amyloid‐β Pathology Exacerbates Aging‐Induced Dysregulation of C1q Expression in Cortical Neurons	27

SARS‐CoV‐2 infection worsens Vascular Dementia (VaD)‐associated neuropathology in mice	27
Genetic and pharmacologic proteasome augmentation ameliorates Alzheimer’s‐like pathology in animal models of AD	26
Late‐life social activity and subsequent risk of dementia and mild cognitive impairment	26
Prevention of release of amyloid beta 1‐42 fibrils by inhibiting Hsc70	26
Repetitive transcranial magnetic stimulation increases synaptic plasticity of cortical axons in the APP‐PS1 mouse model of amyloidosis	26
The detection of GRN mutation carriers by progranulin blood protein levels from finger‐stick collection	26
Mutation in presynaptic protein Bassoon induces tauopathy in vivo	26
A systematic evaluation of hippocampal GABA levels in transgenic mouse models of amyloid and tau	26
Association between dietary inflammatory index score and incident dementia	26
Lecanemab: Amyloid Reduction and Evidence of Downstream Biomarker Modification	25
Differential associations of neighborhood disadvantage, race/ethnicity, and cognitive status with experiences of psychosocial distress in the HABS‐HD cohort	25
Increased CRP and triglyceride level associate with accelerated progression of Alzheimer's disease	25
Sleep spindles and slow oscillations predict cognition and biomarkers of neurodegeneration in mild to moderate Alzheimer's disease	25
Observations on biomarkers in Roche Abeta‐targeting monoclonal antibody trials	25
Homocysteine, neurodegenerative biomarkers, and APOE ε4 in neurodegenerative diseases	25
Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research	24
Development and assessment of analytic methods to improve the measurement of cognition in longitudinal studies of aging through the use of substudies with comprehensive neuropsychological testing	24
From research to realization: How a Texas health plan implemented an academic model of care for Alzheimer's disease	24
Proton pump inhibitors and dementia: A nationwide population‐based study	24
	24
Prevalence of dementia and mild cognitive impairment in indigenous Bolivian forager‐horticulturalists	24
The effect of memantine on cortical network function in frontotemporal lobar degeneration is conditional on baseline GABA physiology	24
Cognitive impairment associated with greater care intensity during home health care	24
Extensive genetic and phenotypic description of MAPT p.R406W in the Flanders‐Belgian population	24
Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study	23
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring announces new editor‐in‐chief for open access, peer reviewed journal	23
	23
Plasma Aβ 42:40 ratio tracks with changes in brain amyloid PET SUVr in the core and open label extension of the phase 2 proof of concept study ban2401‐g000‐201 following treatment with lecanemab in su	23
Diffuse optical tomography for mapping cerebral hemodynamics and functional connectivity in delirium	23
Conversations and decision‐making about nutrition and hydration for people with severe dementia in acute hospitals: a qualitative study	23
Altered Gut Microbiota in Dementia and Mild Cognitive Impairment in Community‐Dwelling Older Adults in Taiwan	23
Proteins translated from tau circular RNAs as drivers for Alzheimer’s disease and frontotemporal dementia	23
Characterization of glial responses in Alzheimer’s disease with cyclic multiplex fluorescent immunohistochemistry and machine learning	23
Echocardiographic measures of the left heart and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: The CABLE study	23
Melatonin, metformin, and ranolazine equally improved cognitive function in rats with doxorubicin‐induced chemobrain	23
The impact of built and social environmental characteristics on incidence and estimated risk of dementia	23
White matter hyperintensity on MRI and plasma Aβ42/40 ratio additively increase the risk of cognitive impairment in hypertensive adults	23
Body mass index predicts lower connectivity in associational fibers of the temporal lobe in older men	23
Racial‐ethnic differences in baseline and longitudinal change in neuropsychological test scores in the NACC Uniform Data Set 3.0	23
Alzheimer's disease genetic risk score and neuroimaging in the FINGER lifestyle trial	23
Erratum	22
Weight loss and risk of dementia in individuals with versus without obesity	22
Long‐term exposure to air pollution and road traffic noise and incidence of dementia in the Danish Nurse Cohort	22
HMGB1‐Mediated Senescence and Brain Inflammation Contributes to Cognitive Dysfunctions	22
Generalizability of findings from a clinical sample to a community‐based sample: A comparison of ADNI and ARIC	22
Longitudinal associations between racial discrimination and brain aging among black older adults	22
Effects of risk factors on longitudinal changes in brain structure and function in the progression of AD	22
Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health‐related comorbidities in a community‐dwelling cohort	22
Lack of bidirectional association between age‐related macular degeneration and Alzheimer's disease: A Mendelian randomization study	22
Association between carotid intima‐media thickness and cognitive decline differs by race	22
Retromer subunit, VPS29, regulates vacuolar‐type ATPase and lysosomal acidification in the aging brain	22
Characterizing molecular and synaptic signatures in mouse models of late‐onset Alzheimer's disease independent of amyloid and tau pathology	22
	22
Rural‐urban differences in diagnostic incidence and prevalence of Alzheimer's disease and related dementias	22
Brain microstructure mediates effects of tau on cognitive decline in early Alzheimer’s disease	21
Who is at risk of dementia? Trajectories of cognitive decline from mild cognitive impairment to dementia and the factors which mediate this decline	21
BIN1 LOAD mutants increase intracellular Aβ by interfering with BACE1 recycling	21
Efficacy of soluble epoxide hydrolase inhibition in a rat model of Alzheimer’s disease	21
A longitudinal 18F‐FDG PET study in asymptomatic stage of genetic Creutzfeldt–Jakob disease	21
In memoriam, Robert C. Bowles, Jr, 1947–2022	21
Neuronal correlates of sleep in neurodegenerative diseases	21
Improving collaboration between palliative care and neurology: Focus on patient, family & healthcare provider experience	21
Issue Information	20
Characterization of altered neuroenergetic patterns in Alzheimer’s Disease using combined FDG‐PET and sodium MRI	20
Sleep apnea and cognition in older APOE4 carriers and non‐carriers	20
Assessing neuroinflammatory differences in FTLD‐Tau vs FTLD‐TDP using free water diffusion	20
Resistance and resilience to Alzheimer’s disease pathology associated with lower severity of other neuropathologic diseases	20
Use of modified Telephone Interview for Cognitive Status (TICS‐M) for cognitive impairment analysis one year after COVID‐19 hospitalization in Brazil	20
MAPS: Music and psychology & social connections – a protocol for a pilot dyadic intervention for caregivers and people living with younger‐onset dementia	20
Preclinical Alzheimer’s Disease accurate prediction using plasma cell‐free RNA sequences	20
Evolution of circulating metabolites through lifespan according to gender and APOE	20
A novel approach to measure awareness of memory decline and its ability to predict clinical progression in cognitively normal older adults	20
Incidence trends of dementia in Czechia: A national registry‐based study over 15 years	20
Bioenergetic and vascular predictors of potential super‐ager and cognitive decline trajectories – A UK Biobank random forest classification study	20
Neurologic manifestations in hospitalized patients with COVID‐19	20
The paradox of Urban AD/ADRD caregiving during COVID‐19 pandemic	20
Management of epilepsy in Alzheimer’s disease in Down syndrome	20
Construction of a questionnaire to evaluate cognitive domains based on the diagnostic criteria of the Diagnostic and Statistical Manual of mental disorders ‐ DSM‐5 for neurocognitive disorders	20
Sex differences in the prevalence of mild behavioral impairment: A systematic review and meta‐analysis	20
Fused multi‐modal similarity network as prior in guiding brain imaging genetic association	20
PAS‐MCI: Design and rationale for a randomized controlled trial to enhance prefrontal cortical plasticity and working memory in individuals with amnestic mild cognitive impairment	20
Neuropsychiatric symptoms of Alzheimer’s dementia and their association with dorsolateral prefrontal cortex TMS evoked potentials	20
Novel unsupervised comprehensive tool for monitoring vascular cognitive impairment following stroke	19
Digital Biomarkers and Wearable Neurotechnologies: A Cost of Privacy and Security for Alzheimer’s Patients	19
Circulating extracellular vesicles of neurovascular origin are elevated in women with severe preeclampsia years after their affected pregnancies	19
Mobile memory gas station: A valid phone screen for cognitive impairment	19
Clinically relevant monitoring of long‐term night‐time behaviour and physiology from the homes of people living with dementia	19
Differential diagnosis of neurodegenerative diseases using an innovative deep learning approach	19
Mild behavioral impairment linked to phenoconversion to Alzheimer’s disease and cortical thinning in mild cognitive impairment	19
PENSA study for the prevention of cognitive decline in APOE‐ɛ4 carriers with subjective cognitive decline: Description of baseline demographic and neuropsychological data of the study population	19
Sex‐adjusted blood biomarkers differentiate AD from LATE	19
No added value of Sex and APOE*4 stratification for Alzheimer’s Disease Genetic Risk Scores	19
Amyloid pathology is associated with semantic loss in patients with subjective cognitive decline	19
The results of dementia care policy implementation in Eastern Taiwan	18
Different cutoffs definitions to evaluate the concordance between CSF Ab42 and Ab42/Ab40 across neurodegenerative diseases	18